SELLAS Life Sciences (SLS) Receivables - Accured (2017)
SELLAS Life Sciences (SLS) reported Receivables - Accured of $800000.0 for Q4 2017.
SELLAS Life Sciences (SLS) has 1 years of Receivables - Accured data on file, last reported at $800000.0 in Q4 2017.
- Quarterly Receivables - Accured changed N/A year-over-year to $800000.0 in Q4 2017, while the trailing twelve-month figure through Dec 2017 was $800000.0 (changed N/A YoY) and the FY2017 annual result came in at $800000.0, changed N/A from the prior year.
- Revenue - Other retreated to -$491000.0 in Q2 2014 per SLS's latest filing, from -$165000.0 in the prior quarter.
- Across five years, Receivables - Accured topped out at $800000.0 in Q4 2017 and bottomed at $800000.0 in Q4 2017.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Acc. Int. Receivables (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 1,216,509.61 Bn | 1,216,509.61 Bn | - | - |
| 2 | Alterity Therapeutics | 764,224.41 Bn | 764,224.38 Bn | - | - |
| 3 | Legend Biotech | 2,716.00 Bn | 2,715.71 Bn | 242.10 Mn | - |
| 4 | Nanobiotix | 2,248.83 Bn | 2,248.77 Bn | - | - |
| 5 | Akari Therapeutics | 1,951.18 Bn | 1,951.17 Bn | - | - |
| 6 | Vertex Pharmaceuticals | 113.69 Bn | 106.44 Bn | 2.59 Bn | - |
| 7 | Evaxion A | 64.16 Bn | 64.14 Bn | - | - |
| 8 | Regeneron Pharmaceuticals | 63.94 Bn | 55.18 Bn | 3.31 Bn | - |
| 9 | Alnylam Pharmaceuticals | 40.13 Bn | 37.12 Bn | 959.66 Mn | - |
| 10 | SELLAS Life Sciences | 1.61 Bn | 1.61 Bn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2017 | 800,000.00 |
| Dec 31, 2017 | 800,000.00 |